Ventyx Biosciences
VTYX
VTYX was delisted on the 3rd of March, 2026.
146 hedge funds and large institutions have $1.67B invested in Ventyx Biosciences in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 17 closing their positions.
241% more call options, than puts
Call options by funds: $8.21M | Put options by funds: $2.41M
124% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 17
19% more capital invested
Capital invested by funds: $1.4B → $1.67B (+$271M)
17% more funds holding
Funds holding: 125 → 146 (+21)
10.2% more ownership
Funds ownership: 75.27% → 85.47% (+10%)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$230M |
| 2 |
Goldman Sachs
New York
|
+$50.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.8M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$45.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$35.6M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$35.4M |
| 4 |
TP
Third Point
New York
|
-$32.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$29.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Millennium Management
New York
| – | -$4.23M | -108,703 | Closed |
|
|
SCM
152
Soleus Capital Management
Greenwich,
Connecticut
| – | -$2.26M | -69,000 | Closed |
|
|
EGI
153
EAM Global Investors
Solana Beach,
California
| – | -$1.51M | -46,189 | Closed |
|
|
JF
154
Jump Financial
Chicago,
Illinois
| – | -$1.15M | -35,070 | Closed |
|
155
Two Sigma Advisers
New York
| – | -$984K | -30,000 | Closed |
|
|
CCMU
156
Cheyne Capital Management (UK)
London,
United Kingdom
| – | -$657K | -20,035 | Closed |
|
|
CPM
157
Connective Portfolio Management
New York
| – | -$492K | -15,000 | Closed |
|
|
GT
158
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$341K | -10,390 | Closed |
|
|
MA
159
MYDA Advisors
Woodmere,
New York
| – | -$328K | -10,000 | Closed |
|
|
HNWAG
160
High Net Worth Advisory Group
Naples,
Florida
| – | -$32.8K | -1,000 | Closed |
|
|
CG
161
Cutler Group
San Francisco,
California
| – | -$23.3K | -600 | Closed |
|
|
ACM
162
Aquatic Capital Management
Chicago,
Illinois
| – | -$3K | -100 | Closed |
|
VTYX Hedge Fund Activity: Q1 2023 in Review
146 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2023, worth a combined $1.67B — up 19% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new VTYX positions and 17 closed out — a net gain of 21 holders — while 47 added to existing stakes and 43 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was venBio Partners, cutting an estimated $45.2M.
- 146 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2023, up from 125 in Q4 2022.
- Funds reported $1.67B of Ventyx Biosciences stock for Q1 2023, up 19% quarter-over-quarter.
- 38 funds opened new Ventyx Biosciences positions in Q1 2023 and 17 closed out, a net change of +21 holders.
- The largest Ventyx Biosciences buyer in Q1 2023 was Fidelity Investments, an estimated $230M added.
- The largest Ventyx Biosciences seller in Q1 2023 was venBio Partners, an estimated $45.2M sold.
Based on aggregated 13F filings for Q1 2023.